For these reasons, effective therapies alleviating mucositis as the supportive care of cancers is a highly significant issue for cancer patients, in particular those with head and neck cancer (HNC) receiving CRT.
← all excerpts
The post hoc analysis comparing the severity grades of chemoradiotherapy-induced oral mucositis scored between the central and local assessors in a multicenter, randomized controlled trial of rebamipide for head and neck cancer.
1
—
—